Demographic, clinical, laboratory and echocardiographic features of cirrhotic patients according to presence or absence of F2-F3 oesophageal varices.

<p>Demographic, clinical, laboratory and echocardiographic features of cirrhotic patients according to presence or absence of F2-F3 oesophageal varices.</p

Cirrhotic patients with and without ascites compared to control hypertensive population had significantly higher NT pro-BNP plasma levels.

<p>Cirrhotic patients with and without ascites compared to control hypertensive population had significantly higher NT pro-BNP plasma levels.</p

Relationship between NT-pro-BNP levels and clinical and echocardiographic data on linear regression analysis in cirrhotic patients.

<p>Relationship between NT-pro-BNP levels and clinical and echocardiographic data on linear regression analysis in cirrhotic patients.</p

NT pro BNP serum levels and echocardiographic features of 58 cirrhotic patients and 28 matched controls.

<p>NT pro BNP serum levels and echocardiographic features of 58 cirrhotic patients and 28 matched controls.</p

Demographic, clinical, laboratory and echocardiographic features of cirrhotic patients according to presence or absence of ascites.

<p>Demographic, clinical, laboratory and echocardiographic features of cirrhotic patients according to presence or absence of ascites.</p

Predictive value of HCV RNA results in the CTM and ART at week 4 (a) and week 8/12 (b) after start of therapy with a protease inhibitor.

<p>TND  =  target not detected; DET  =  HCV RNA detected; TND/TND  =  HCV not detected in both assays; TND/DET  =  HCV RNA detected by only one assay; DET/DET: HCV RNA detected by both assays. *Patients with unavailable virological treatment outcome were excluded from analysis.</p

Measured HCV RNA level by the ART and CTM in samples obtained 24 weeks after TVR/BOC therapy with a detectable HCV RNA in at least one of the two assays.

<p>The discordant results in ten samples (“TVR 4–6” and “BOC 18–24”) would have led to different treatment decisions (treatment discontinuation due to detectable HCV RNA). In a single sample the ART measured a higher HCV RNA level than the CTM (“BOC 5”).</p><p>Measured HCV RNA level by the ART and CTM in samples obtained 24 weeks after TVR/BOC therapy with a detectable HCV RNA in at least one of the two assays.</p

Correlation between the CTM and the ART in samples with quantifiable HCV RNA levels.

<p>r: Spearman correlation; p: p-value.</p

HCV RNA levels according to ART and CTM in samples obtained 12 weeks after TVR treatment that yielded levels ≥50 IU/ml in at least one of the two assays.

<p>The discordant results in one sample (“TVR 3”) would have led to a different treatment decision (treatment discontinuation based on HCV RNA levels>1000 IU/ml at week 4).</p><p>HCV RNA levels according to ART and CTM in samples obtained 12 weeks after TVR treatment that yielded levels ≥50 IU/ml in at least one of the two assays.</p

HCV RNA levels according to ART and CTM in samples obtained 4 weeks after start of TVR/BOC therapy that yielded levels ≥50 IU/ml in at least one of the two assays.

<p>The discordant results in two samples (“TVR 1” and “TVR 2”) would have led to different treatment decisions (treatment discontinuation based on HCV RNA levels>1000 IU/ml at week 4). In a single sample the ART measured a higher HCV RNA level than the CTM (“TVR 8”).</p><p>HCV RNA levels according to ART and CTM in samples obtained 4 weeks after start of TVR/BOC therapy that yielded levels ≥50 IU/ml in at least one of the two assays.</p